The group has received a grant from the Catalan Society of Rheumatology and the objective is to work towards early detection and even more personalized treatments
Researchers from the Biomarkers of Disease and Molecular Mechanisms (DIBIOMEC) research group of the IISPV and the Hospital Universitari Joan XXIII de Tarragona are working to improve the diagnosis of rheumatoid arthritis. The task has received a grant from the Societat Catalana de Reumatologia and the aim is to work towards early detection and even more personalized treatments. The grant will allow the development of a clinical study focused on rheumatoid arthritis, a project led by Dr. Samantha Rodríguez and promoted by Dr. Matilde Rodríguez Chacón, PI of the research group.
The study will validate a panel of biomarkers previously identified by DIBIOMEC that could change the way autoimmune disease is diagnosed and treated. In fact, these have shown, in the eyes of the research team, great potential in detecting the disease in early stages and predicting the response to treatments.
By analyzing serum samples from patients at different stages of rheumatoid arthritis, the study aims to confirm the clinical utility of the biomarkers they are working with.
The DIBIOMEC group, with extensive experience in the study of biomarkers in inflammatory and oncological diseases, has international patents in the field of molecular diagnostics. With this new line of work, the group transfers its knowledge in the field of rheumatology, to shorten the time of diagnosis and improve the therapeutic approach to the disease from its earliest stages.
Facebook 
Mail 
WhatsApp 
